2 results match your criteria: "Institute of Medical Sciences University of Toronto Toronto ON Canada.[Affiliation]"
Background: The bleeding risks for nonsyndromic platelet function disorders (PFDs) that impair aggregation responses and/or cause dense granule deficiency (DGD) are uncertain.
Objectives: Our goal was to quantify bleeding risks for a cohort of consecutive cases with uncharacterized PFD.
Methods: Sequential cases with uncharacterized PFDs that had reduced maximal aggregation (MA) with multiple agonists and/or nonsyndromic DGD were invited to participate along with additional family members to reduce bias.
Article Synopsis
- Newer antihyperglycaemic agents (AHA) like DPP4i, GLP1RA, and SGLT2i show a lower risk of hypoglycaemia compared to traditional treatments like sulfonylurea or insulin, but their risk against placebo was unclear.
- A systematic review analyzed trials over 12 weeks to evaluate the risk of both any and severe hypoglycaemia associated with AHA and metformin compared to placebo.
- Results indicated that AHA did not significantly increase hypoglycaemia risk whether used alone or with metformin, while metformin alone and early dual therapy initiation raised the risk of any hypoglycaemia.